Gefarnate | CAS#51-77-4 | antiulcer agent

MedKoo Cat#: 561640 | Name: Gefarnate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Gefarnate is an antiulcer agent that stimulates in-vitro secretion of mucin-like glycoprotein in conjunctival tissue. It also ameliorates corneal epithelial damage in animal dry-eye models.

Chemical Structure

Gefarnate

CAS#51-77-4

Theoretical Analysis

MedKoo Cat#: 561640

Name: Gefarnate

CAS#: 51-77-4

Chemical Formula: C27H44O2

Exact Mass: 400.3341

Molecular Weight: 400.65

Elemental Analysis: C, 80.94; H, 11.07; O, 7.99

Price and Availability

Size	Price	Availability	Quantity
50mg	USD 250.00	2 Weeks
100mg	USD 450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Gefarnate; Gefarnyl; Geranyl farnesylacetate; Gefarnato; Gefanil; Gefarnatum; DA-688; DA688; DA 688; NSC138947; NSC 138947; NSC-138947

IUPAC/Chemical Name

[(2E)-3,7-Dimethylocta-2,6-dienyl] (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate

InChi Key

ZPACYDRSPFRDHO-ROBAGEODSA-N

InChi Code

InChI=1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3/b24-16+,25-18+,26-20+

SMILES Code

C/C(C)=C\CC/C(C)=C/CC/C(C)=C/CCC(OC/C=C(C)/CC/C=C(C)/C)=O

Appearance

Liquid

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Gefarnate is a drug used for the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of dry eye syndrome.

In vitro activity:

TBD

In vivo activity:

Exposure to gefarnate at 0.002, 0.006, or 0.02 mg/mL for 24 hours increased the secretion of mucin-like glycoprotein from isolated rabbit conjunctival tissue in a dose-dependent manner. The secretion of mucin-like glycoprotein showed statistically significant differences at gefarnate concentrations of 0.006 and 0.02 mg/mL compared to the vehicle (0 mg/mL of gefarnate). Reference: Clin Ophthalmol. 2013;7:211-7. https://pubmed.ncbi.nlm.nih.gov/23386781/

	Solvent	mg/mL	mM
Solubility
	DMSO	31.3	78.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 400.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Dota A, Takaoka-Shichijo Y, Nakamura M. Gefarnate stimulates mucin-like glycoprotein secretion in conjunctival tissue and ameliorates corneal epithelial damage in animal dry-eye models. Clin Ophthalmol. 2013;7:211-7. doi: 10.2147/OPTH.S39061. Epub 2013 Jan 29. PMID: 23386781; PMCID: PMC3563349. 2. Ohta Y, Kobayashi T, Imai Y, Inui K, Yoshino J, Nakazawa S. Effect of gefarnate on acute gastric mucosal lesion progression in rats treated with compound 48/80, a mast cell degranulator, in comparison with that of teprenone. Biol Pharm Bull. 2005 Aug;28(8):1424-30. doi: 10.1248/bpb.28.1424. PMID: 16079487.

In vitro protocol:

TBD

In vivo protocol:

1: Akagi M, Amagase K, Murakami T, Takeuchi K. Irsogladine: overview of the mechanisms of mucosal protective and healing- promoting actions in the gastrointestinal tract. Curr Pharm Des. 2013;19(1):106-14. Review. PubMed PMID: 22950502. 2: Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J. Therapeutic targets in dry eye syndrome. Drug News Perspect. 2008 Apr;21(3):166-76. Review. PubMed PMID: 18560615. 3: Carmine AA, Brogden RN. Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs. 1985 Aug;30(2):85-126. Review. PubMed PMID: 3928324. 4: Lux G, Rösch W. [Conservative treatment of gastric ulcer]. Med Klin. 1980 Aug 29;75(18):638-44. Review. German. PubMed PMID: 6106882. 5: Guslandi M. Review: effect of anti-ulcer drugs on gastric mucous barrier and possible cyclic AMP involvement. Int J Clin Pharmacol Ther Toxicol. 1980 Mar;18(3):140-3. Review. PubMed PMID: 6247291. 6: Vezzadini P, Ferri GL. [Medical therapy of gastric ulcer]. Clin Ter. 1979 May 15;89(3):309-17. Review. Italian. PubMed PMID: 380884.